Stimuli-responsive dual drugs-conjugated polydopamine nanoparticles for the combination photothermal-cocktail chemotherapy

Publication date: Available online 21 February 2020Source: Chinese Chemical LettersAuthor(s): Lei Zhou, Chang Du, Rong Zhang, Changming DongAbstractWe developed one-pot aqueous copolymerization of two dopamine prodrugs to prepare dual drugs-conjugated polydopamine nanoparticles (PDOXCBs), which integrated near infrared (NIR)-mediated photothermal effect with cocktail chemotherapy into one copolymer nanoparticle. Upon a mild NIR irradiation (808 nm, 1 W/cm2, 10 min), PDOXCBs gradually heated aqueous solution over 12.8―13.9 °C, which accordingly enhanced in vitro dual doxorubicin (DOX) and chlorambucil (CB) drug-release with assistance of the other stimuli of pH 5.0 and 10 mmol/L D,L-dithiothreitol (DTT). The combination photothermal-cocktail chemotherapy (PTT-CCT) treatment based on PDOXCB27 plus NIR irradiation gave a highly lowered half maximal inhibitory concentration (IC50) of 2.23 µg/mL and a combination index of 0.36, displayinga superior synergistic effect between PTT and CCT in vitro.Graphical abstractThe dual anticancer drugs-conjugated PDOXCBs nanoparticles were facilely prepared by aqueous precipitation copolymerization of two dopamine prodrugs, which integrated intrinsic photothermia of PDA with the polyprodrug-induced cocktail chemotherapy for potentialcombination cancer PTT-CCTapplication.
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research

Related Links:

CONCLUSIONS: Overall survival was good in both subgroups and comparable to literature. The mean costs per patient differ between the watch-and-wait subgroup (€6713) and the total mesorectal excision subgroup (€17,108). No comparison between the groups could be made. Based on the results of this study, the current strategy, where patients with a clinical complete response are treated in a watch-and-wait policy, and patients with an incomplete response are treated with total mesorectal excision, is likely to be (cost)saving. See Video Abstract at http://links.lww.com/DCR/B177. RESULTADOS ONCOLÓGICOS Y COS...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
We report a case of the pathologically evaluated antitumor effect of pembrolizumab, a programmed death-1 immune checkpoint inhibitor antibody, in G-CSF-producing bladder cancer. A 53-year-old male patient underwent 4 courses chemotherapy with a combination of gemcitabine and carboplatin before a radical cystectomy with ileal neobladder. Four months after the surgery, local recurrence was detected in the pelvis and therefore pembrolizumab was used. One week after its administration, the patient showed increased mucus in his urine. A computed tomography scan and cystoscopy revealed a fistula between the ileum and the neoblad...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
Conclusions: We conclude that AS-IV could inhibit cervical cancer invasion by inducing autophagy in cervical cancer cells. Since iTRAQ combination by PRM has been observed to be useful in identifying macromolecular target compounds, it may be considered as a novel strategy in the screening of anticancer compounds used in the treatment of cervical cancer. PMID: 32265995 [PubMed - in process]
Source: Cellular and Molecular Biology Letters - Category: Biochemistry Authors: Tags: Cell Mol Biol Lett Source Type: research
Conditions:   Pancreatic Adenosquamous Carcinoma;   Resectable Pancreatic Adenocarcinoma;   Pancreatic Cancer Interventions:   Drug: Oxaliplatin;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Procedure: Resection;   Other: Questionnaire Administration Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Authors: Source Type: podcasts
Authors: Yin G, Hua X, Liao Y, Huang C, Fan X Abstract The aim of this work was to determine whether tumor resection could improve the prognosis of M1a non-small-cell lung cancer (NSCLC) patients. We obtained patient data from the Surveillance, Epidemiology, and End Results (SEER) database and used propensity score matching (PSM) to reduce the influence of confounding variables. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors, and the prediction results were visualized using the nomogram. A total of 772 patients with and without tumor resection were enrolled ...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Medical centers across the country have slowed or stopped the enrollment of new patients in mesothelioma clinical trials because of the all-consuming COVID-19 pandemic. The pause in enrollment options could be critical for newly diagnosed patients with pleural mesothelioma, whose life expectancy is often just six to 12 months. Clinical trials are research studies where patients can find cutting-edge treatments not yet approved by the U.S. Food and Drug Administration. Those experimental treatments go beyond standard of care, which generally has not been effective for this rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The targeted agent encorafenib has been approved by the FDA) for use in BRAF-positive colorectal cancer (CRC). It offers a subgroup of patients with CRC a chemotherapy-free treatment option.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
CONCLUSION: Although women with uterine confined leiomyosarcoma experience high recurrence rates and poor survival outcomes, adjuvant treatment does not appear to confer a survival benefit. PMID: 32266798 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
Contributors : Y Zhang ; D Wang ; D Shen ; Y Luo ; Y Q CheSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensAnthracycline-induced liver injury (AILI) is one of the serious complications of anthracycline-based adjuvant chemotherapy for postoperative breast cancer patients. Exosomal miRNAs, as signaling molecules in intercellular communication, play the essential roles in the drug-induced liver injury (DILI). However, the expression profiles of them in patients with AILI remains unknown. Seven post-chemotherapy patients were recruited in this study. After isolated plasma-derived exoso...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Chemotherapy | China Health | Nanotechnology